Betazok

Betazok

metoprolol

Manufacturer:

AstraZeneca

Distributor:

Zuellig
Concise Prescribing Info
Contents
Metoprolol succinate
Indications/Uses
HTN. Angina pectoris. Disturbances of cardiac rhythm including supraventricular tachycardia. Maintenance treatment after MI. Functional heart disorders w/ palpitations. Migraine prophylaxis. 23.75 mg: Symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy.
Dosage/Direction for Use
Mild to moderate HTN Adult 50 mg once daily, may increase to 100-200 mg once daily &/or combined w/ other antihypertensive agents. Adolescent & childn ≥6 yr Initially 1 mg/kg once daily, may increase to a max daily dose of 2 mg/kg not exceeding 50 mg once daily. Angina pectoris 100-200 mg once daily. May combine w/ other anti-anginal agents if needed. Cardiac arrhythmias 100-200 mg once daily. MI Maintenance therapy: 200 mg once daily. Functional heart disorders w/ palpitations 100 mg once daily, may increase to 200 mg if needed. Migraine prophylaxis 100-200 mg once daily. Chronic heart failure Initially 25 mg once daily during the 1st 2 wk. May be doubled up to a max of 200 mg once daily (or highest tolerated dose). Patient w/ NYHA III-IV Initially ½ of 25 mg tab once daily on the 1st wk, doubled every 2nd wk up to max target dose of 200 mg once daily (or to the highest tolerated dose).
Administration
May be taken with or without food: Swallow whole w/ liqd, do not chew/crush. May be halved along the score-line, but the divided halves should not be chewed/crushed.
Contraindications
Hypersensitivity to metoprolol or other β-blockers. 2nd or 3rd degree AV block, unstable decompensated cardiac heart failure (pulmonary oedema, hypoperfusion or hypotension), continuous/intermittent inotropic therapy acting through β-receptor agonism, clinically relevant sinus bradycardia, sick-sinus syndrome, cardiogenic shock, severe peripheral arterial circulatory disorder. Patients w/ suspected acute MI w/ heart rate <45 beats/min, P-Q interval >0.24 sec, systolic BP <100 mmHg.
Special Precautions
Avoid concomitant IV administration of the verapamil-type Ca antagonists. Asthma. Risk of interfering w/ carbohydrate metabolism or masking hypoglycemia. May aggravate preexisting AV conduction disorder of moderate degree; symptoms of peripheral arterial circulatory disorders. α-blocker should be given concomitantly for patients w/ pheochromocytoma. Lower doses or gradually w/draw therapy if increasing bradycardia develops. Avoid abrupt w/drawal. Gradually discontinue treatment over at least 2 wk when the dose is reduced by 1/2 in each step down to the final step when a whole 25 mg tab is reduced to a 1/2 tab. Do not stop treatment in patients undergoing surgery. Avoid acute initiation of high doses to patients undergoing non-cardiac surgery. Anaphylactic shock. Occasional dizziness or fatigue may occur which may impair ability to drive or use machines. Pregnancy & lactation. Childn <6 yr.
Adverse Reactions
Fatigue. Bradycardia, postural disorders, cold hands & feet, palpitation; dizziness, headache; nausea, abdominal pain, diarrhoea & constipation; dyspnoea on exertion.
Drug Interactions
May raise plasma levels w/ antiarrhythmics, antihistamines, H2-receptor antagonists, antidepressants, antipsychotics, & COX-2-inhibitors. Lowered plasma conc w/ rifampicin. Raised plasma conc w/ alcohol & hydralazine. Sympathetic ganglion blocking agents, other β-blockers (ie, eye drops), MAOIs; clonidine. Increased -ve inotropic & chronotropic effects w/ Ca antagonists of the verapamil & diltiazem type. May enhance -ve inotropic & dromotropic effect of antiarrhythmic agents of the quinidine type & amiodarone. May increase AV conduction time & induce bradycardia w/ digitalis glycosides. Enhanced cardiodepressant effect w/ inhalation anaesth. May decrease antihypertensive effect w/ indomethacin or other prostaglandin synthetase inhibiting drugs. Interfered BP control w/ adrenaline.
MIMS Class
Beta-Blockers
ATC Classification
C07AB02 - metoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Presentation/Packing
Form
Betazok CR tab 23.75 mg
Packing/Price
28's
Form
Betazok CR tab 95 mg
Packing/Price
105's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in